Even though professional principles in investor relations do apply to all industries, IR executives face important sector-specific developments and challenges. A recent whitepaper by Bloomberg and IR Magazine summarizes a roundtable held with IR professionals, buy-side and sell-side analysts in the healthcare sector.
Characterized by inherent long-term business strategies and goals, the healthcare industry faces increasing pressure from short-term oriented imvestors. At the same time, shortened investment horizons and the risk of high volatility requires IR professionals to have access to the same high-standard data analysis and monitoring tools as their buy- and sell-side counterparts. How to manage the conundrum of short-term trading and long-term business goals (and long-term oriented investors)? The challenge is to provide strong arguments and perspectives without over-selling the stock or ignoring rumors on the market. “Framing the issues and providing the necessary positioning to educate analysts and investors about the stock”, as the authors put it, remains the key to successful IR in the healthcare sector. Sounds a little bit too vague? Read further details in the whitepaper “A Healthy Debate: Navigating A Changing Investor Relations Landscape in the Healthcare Sector”!
According to a study by researchers from the Center for Regenerative Therapies Dresden (CRTD, Dresden, Germany), it is possible to increase the brain’s pool of brain stem cells by overexpressing cdk4 and cyclinD1 via the introduction of programmed viral vectors. Subsequently, the increased stem cell pool leads to the increased production of neuronal cells, reportsDie Welt. The study published in the Journal of Experimental Medicine was conducted in the brains of adult mice and may allow researchers to better understand the function of neuronal stem cells and to develop new therapies to combat neurodegenerative diseases.
Brain cell formation is also boosted by certain antidepressant drugs, reports Jessica Hamzelou in New Scientist. The study conducted at King’s College, London found that antidepressants such as sertraline work by acting on glucocorticoide receptors. However, they activate the receptor in a different way than glucocorticoide hormones.
Hayley Crawford in the New Scientist introduces the world’s first computerized map of the human brain. This novel Human Brain Atlas developed by the Allen Institute for Brain Research in Seattle (Wash.) is an interactive tool scientists can use to search for data, e.g. all known locations in the brain where targets of a certain drug are expressed.
In Forbes, Parmy Olson reports on Seedcamp, a concept developed in 2007 by Index Ventures partners Saul Klein and Reshma Sohoni. Seedcamps are conferences in which start-ups present their business ideas and have the opportunity to sell a 8-10% equity stake in return for 50,000 Euros and a year-long support program. The conferences are held throughout Europe, but also in India, Singapore and South Africa. The program at present support 38 start-ups and is now expanding to the US.
The Economist reports on Asthmapolis, a US-based company, and its Spiroscout inhaler that comes with a built-in Global Positioning System locator and a wireless link to the internet. Whenever someone uses the inhaler, it broadcasts the location and time to a central computer. Asthmapolis plots and analyses the data, and sends weekly reports to participating patients and their doctors summarizing the observations and making recommendations. The device allows to identify threats patients are unaware of and helps doctors identify those patients whose asthma is not under proper control.
Roni Caryn Rabin in The New York Times reports on a recent study in more than 800 elderly people. Researchers observed that older people suffering from mild memory and cognition problems seem to be less likely to develop full-blown Alzheimer’s disease if they receive proper treatment for conditions such as high blood pressure, diabetes and cholesterol.
Neurobiologist Jörn Niessing in Der Spiegel explains how the human nose is able to differentiate between thousands of different odors. The trick is done by generalization and subsequent separation of the information obtained by the different elements of the olfactory system. Latest insights into the olfactory systems of zebrafish also explain why certain odors smell differently in different concentrations.
Claudia Füßler in Die ZEIT reports about humans contracting malaria in Southeast Asia by infections with Plasmodium knowlesi, a parasite usually infecting egret monkeys (Macaca fascicularis). P. knowlesi is the most rapidly proliferating malaria parasite, doubling its numbers in infected humans every 24 hours. In addition, it can be easily mistaken for P. malaria under the microscope. As a result, prophylaxis is highly recommended when visiting these regions.
Die ZEIT also reports on figures by the WHO demonstrating that each year about 25,000 people in the EU die from infections with bacteria resistant to antibiotics. The article cites WHO director general Margaret Chan as saying, a “post-antibiotic era” with people dying from common infections just as they did centuries ago is approaching fast. She attributes the spread of multi-resistant pathogens to trifling and unreasonably prescriptions of antibiotics which in addition are still sold as OTC medications in many European countries.
The Economist, too, is dealing with the problem and explains why big pharma has all but abandoned the development of novel antibiotics and why this is a promising ground for biotechnology firms.
Alex Knapp in Forbes introduces a technology beyond antibiotics to combat antibiotic-resistant bacteria and infectious diseases like Methicillin-resistant Staphylococcus aureus, known as MRSA. IBM and Singapore’s Institute of Bioengineering and Nanotechnology are developing biodegradable nanoparticles that – once in the body – polymerize into structures able to attach to bacterial cell walls and membranes. The interaction is based on the specific electrostatic properties of bacterial cell walls which differ from human blood cells or infected tissue. Subsequently the polymers physically break through the walls and membranes and destroy the bacteria without harming the surrounding human tissue.
Matthew Herper, also in Forbes proclaims the definitive end of the blockbuster drug, and explains why this leads to rising health care costs. For Herper, the end of the blockbuster era will come in November when Lipitor, the last branded drug among the 15 most used medicines in the US, will go off patent.
Helen Coster, also in Forbes, introduces a US startup, D. Light, that sells low-price portable, rechargeable, solar-powered lights. The most advanced model provides up to 12 hours of light and also comes with a cell phone charger. The lights are sold in rural areas and urban slums in more than 30 Asian, South American, and African countries and enable inhabitants to extend their work day and provide kids with more time to study.
The New Scientistreports on the interesting observation in mice that symptoms of Alzheimer’s disease disappear if the mice are made to overexpress HSP70 heat shock protein which re-folds or disposes of proteins involved in the disease.
Micromet, Inc. (NASDAQ: MITI) yesterday evening announced the presentation of pre-clinical data on its BiTE antibody MT112/BAY 2010112, discovered and developed in collaboration with Bayer HealthCare Pharmaceuticals, at the 102nd Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida.
The data (poster # 4561) demonstrate the potent activity of the BiTE antibody against human cancer cell lines and inhibition of tumor growth in animal models. MT112/ BAY 2010112 directed human and non-human primate T cells against PSMA-positive human prostate cancer cells, resulting in highly efficient cancer cell destruction. In mice, daily doses of MT112/BAY 2010112 as low as 0.05 milligram/kilogram were sufficient to inhibit growth of tumors from human prostate cancer cells.
During the course of the meeting, the Company also presented preclinical data on MT110, its BiTE antibody targeting epithelial cell adhesion molecule (EpCAM). Results reported (poster # 1790) provide further validation of EpCAM as a cancer stem cell target, and show utility of MT110 to eradicate cancer stem cells derived from breast and hepatocellular carcinoma.
